Trial Profile
Triple Subconjunctival Bevacizumab Injection for Early Recurrent Pterygium. One Year Follow-up
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Recurrent pterygium
- Focus Therapeutic Use
- 21 Dec 2013 New trial record